Chemotherapy combination with anti-angiogenic monoclonal antibody

This page covers all Chemotherapy combination with anti-angiogenic monoclonal antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting DNA (chemotherapy); VEGF (bevacizumab), DNA (platinum agents), microtubules (paclitaxel), VEGF (bevacizumab), DNA (carboplatin), microtubules (paclitaxel), VEGF (bevacizumab).

Targets

DNA (chemotherapy); VEGF (bevacizumab) · DNA (platinum agents), microtubules (paclitaxel), VEGF (bevacizumab) · DNA (carboplatin), microtubules (paclitaxel), VEGF (bevacizumab) · VEGF (bevacizumab component); topoisomerase I, thymidylate synthase, DNA (FOLFOXIRI components)

Phase 3 pipeline (4)

• FOLFOX/ FOLFIRI with bevacizumab · Dutch Colorectal Cancer Group · Oncology
  FOLFOX/FOLFIRI chemotherapy regimens combined with bevacizumab inhibit tumor cell division and block new blood vessel formation to starve tumors of nutrients.
• Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab · Lee's Pharmaceutical Limited · Oncology
  This combination regimen uses platinum-based chemotherapy and a taxane to damage cancer cell DNA, combined with an anti-angiogenic monoclonal antibody to block tumor blood vessel formation.
• carboplatin paclitaxel bevacizumab · Gruppo Oncologico Italia Meridionale · Oncology
  This combination uses carboplatin and paclitaxel as chemotherapy agents to damage cancer cell DNA and disrupt microtubules, while bevacizumab blocks angiogenesis by inhibiting vascular endothelial growth factor (VEGF).
• FOLFOXIRI with bevacizumab · Dutch Colorectal Cancer Group · Oncology
  FOLFOXIRI with bevacizumab combines three chemotherapy drugs (fluorouracil, oxaliplatin, and irinotecan) with an anti-angiogenic monoclonal antibody to kill colorectal cancer cells and block tumor blood vessel formation.